Adjuvant vaccine plus immunotherapy for high-risk early lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether giving a personalized cancer vaccine (Intismeran) with or without an immunotherapy drug (pembrolizumab) after lung cancer surgery can help prevent the cancer from coming back in patients with early-stage, high-risk non-small cell lung cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with Stage I non-small cell lung cancer (tumor ≤4 cm) with high-risk features like tumor size >2 cm, invasive growth, or aggressive appearance
- Had complete surgical removal of the lung cancer with no other prior cancer treatment (chemotherapy, immunotherapy, radiation, or targeted therapy)
- Able to provide a tissue sample from your recent surgery and a blood sample
- If HIV-positive, must have well-controlled HIV on antiretroviral therapy; if hepatitis B or C positive, must have received appropriate antiviral treatment with undetectable viral levels
- No significant heart disease in the past year, no active autoimmune conditions requiring recent treatment, and no history of lung inflammation requiring steroids
- Fully recovered from surgery with no ongoing surgical complications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (sintilimab) with chemotherapy to shrink advanced lung cancer that cannot be removed with surgery. The goal is to see if the cancer becomes operable after treatment and to improve outcomes.
This trial is for people with non-small cell lung cancer who have already had immunotherapy and chemotherapy before surgery, followed by complete removal of the tumor. It tests whether continuing immunotherapy after surgery (adjuvant treatment) can lower the risk of cancer coming back compared to just watching and waiting.
This trial tests whether combining an immunotherapy drug (adebrelimab or retlirafusp alfa) with another drug (recaticimab) and chemotherapy helps shrink lung cancer before surgery. The goal is to see if this approach improves outcomes for people with resectable non-small cell lung cancer.
This trial tests a combination of immunotherapy (tislelizumab), a targeted therapy (anlotinib), and standard chemotherapy before and after surgery for people with early-stage but high-risk lung cancer. The goal is to see if this treatment shrinks the tumor, makes surgery more effective, and helps prevent the cancer from coming back.
This trial tests whether giving a type of immunotherapy (sintilimab) along with chemotherapy before and after surgery to remove the main lung tumor can help people with advanced non-small cell lung cancer. The goal is to see if this approach improves outcomes compared to standard treatment.
This trial studies whether adding immune treatment and chemotherapy around the time of lung tumor removal improves outcomes for people with operable non-small cell lung cancer (NSCLC). You may qualify if your cancer can be surgically removed and your tumor tests meet required biomarker rules.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.